Promising new approach for rare vasculitis shows potential in major trial

This study tested whether a drug called rituximab works better than standard treatments to bring a rare disease called eosinophilic granulomatosis with polyangiitis (EGPA) under control. EGPA causes inflammation of small blood vessels, leading to organ damage. The trial involved 107 adults with newly diagnosed or relapsing EGPA. Researchers compared a rituximab-based regimen to conventional therapy, aiming to achieve remission with lower steroid doses.